


CSF1R-IN-23

Cat. No.:	HY-158148
CAS No.:	2935480-17-2
Molecular Formula:	C ₂₇ H ₃₇ N ₃ O ₂
Molecular Weight:	435.6
Target:	c-Fms
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC ₅₀ of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable ^[1] .								
In Vitro	<p>CSF1R-IN-23 (0-10 μM, 30 min) inhibits autophosphorylation of CSF1R in cells RAW264.7 and microglial cells EOC20, without significant cytotoxicity^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>EOC20 and RAW264.7</td> </tr> <tr> <td>Concentration:</td> <td>0-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>30 min</td> </tr> <tr> <td>Result:</td> <td>Inhibited phosphorylation of CSF1R.</td> </tr> </table>	Cell Line:	EOC20 and RAW264.7	Concentration:	0-10 μM	Incubation Time:	30 min	Result:	Inhibited phosphorylation of CSF1R.
Cell Line:	EOC20 and RAW264.7								
Concentration:	0-10 μM								
Incubation Time:	30 min								
Result:	Inhibited phosphorylation of CSF1R.								
In Vivo	<p>CSF1R-IN-23 (0.5 mg/kg, i.p. every two days for 4 doses) ameliorates the Lipopolysaccharide (HY-D1056)-induced neuroinflammation in C57BL/6J mice model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>LPS-induced neuroinflammation in C57BL/6J mice model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p., every two days for 4 doses</td> </tr> <tr> <td>Result:</td> <td>Eliminated the 76% microglia in hippocampus, cortex, and thalamus.</td> </tr> </table>	Animal Model:	LPS-induced neuroinflammation in C57BL/6J mice model ^[1]	Dosage:	0.5 mg/kg	Administration:	i.p., every two days for 4 doses	Result:	Eliminated the 76% microglia in hippocampus, cortex, and thalamus.
Animal Model:	LPS-induced neuroinflammation in C57BL/6J mice model ^[1]								
Dosage:	0.5 mg/kg								
Administration:	i.p., every two days for 4 doses								
Result:	Eliminated the 76% microglia in hippocampus, cortex, and thalamus.								

REFERENCES

[1]. Baek J, et al., Targeting the CSF-1/CSF-1R Axis: Exploring the Potential of CSF1R Inhibitors in Neurodegenerative Diseases. J Med Chem. 2024 Apr 11;67(7):5699-5720.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA